Detalhe da pesquisa
1.
Dynamic nature of BRAF or KRAS p.G12C mutations in second-line therapy for advanced colorectal cancer patients: do early and late effects exist?
Br J Cancer
; 130(5): 777-787, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38191609
2.
Real-life use of ramucirumab in gastric cancer in Spain: the RAMIS study.
Future Oncol
; 17(14): 1777-1791, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33590772
3.
On the Effect of Triplet or Doublet Chemotherapy in Advanced Gastric Cancer: Results From a National Cancer Registry.
J Natl Compr Canc Netw
; 14(11): 1379-1388, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27799509
4.
Correction to: Optimism and social support as contributing factors to spirituality in Cancer patients.
Support Care Cancer
; 29(6): 3375-3376, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33742246
5.
Current professional standing of young medical oncologists in Spain: a nationwide survey by the Spanish Society of Medical Oncology + MIR section.
Clin Transl Oncol
; 25(3): 796-802, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36418642
6.
Does HER2 status influence in the benefit of ramucirumab and paclitaxel as second line treatment of advanced gastro-esophageal adenocarcinoma? Data from the AGAMENON-SEOM registry.
J Cancer Res Clin Oncol
; 149(7): 4077-4089, 2023 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-36042046
7.
Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer: A real-world data, non-inferiority analysis.
J Geriatr Oncol
; 9(3): 254-264, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29242093
8.
SEOM clinical guidelines (2021).
Clin Transl Oncol
; 24(4): 611-612, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35362852
9.
Prognostic and predictive markers of response to treatment in patients with locally advanced unresectable and metastatic pancreatic adenocarcinoma treated with gemcitabine/nab-paclitaxel: Results of a retrospective analysis.
J Cancer Res Ther
; 13(2): 240-245, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28643741
10.
Gemcitabine and capecitabine as third- or later-line therapy for refractory advanced colorectal cancer: a retrospective study.
Anticancer Res
; 33(9): 4089-96, 2013 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-24023354